Molecular analysis of PML-RAR alpha fusion mRNA detected by reverse transcription-polymerase chain reaction assay in long-term disease-free acute promyelocytic leukaemia patients

Br J Haematol. 1995 Aug;90(4):966-8. doi: 10.1111/j.1365-2141.1995.tb05228.x.

Abstract

By use of RT-PCR of PML/RAR alpha, we evaluated bone marrow aspirates in 10 patients with APL in long-term disease-free status after induction chemotherapy and consolidation (median 54 months: range 33-101 months from complete remission). All patients were in clinical and cytogenetic remission at the time of molecular evaluation (range 32-96 months from CR). All patients but one were found to be RT-PCR negative at the molecular level for the expression of PML-RAR alpha transcript, confirming that the majority of the patients with long-term survival of APL are characterized by the eradication of the neoplastic clone.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bone Marrow / pathology
  • Disease-Free Survival
  • Female
  • Gene Rearrangement
  • Humans
  • Leukemia, Promyelocytic, Acute / genetics*
  • Male
  • Middle Aged
  • Neoplasm, Residual
  • Oncogene Proteins, Fusion / genetics*
  • Polymerase Chain Reaction
  • RNA, Messenger / analysis*
  • Receptors, Retinoic Acid / genetics*
  • Retinoic Acid Receptor alpha

Substances

  • Oncogene Proteins, Fusion
  • RARA protein, human
  • RNA, Messenger
  • Receptors, Retinoic Acid
  • Retinoic Acid Receptor alpha